View:
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. 1)
Under the Securities Exchange Act of 1934*
PDL BioPharma, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.01 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
69329Y104
- --------------------------------------------------------------------------------
(CUSIP Number of Class of Securities)
Daniel S. Loeb
Third Point LLC
390 Park Avenue
New York, NY 10022
(212) 224-7400
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Copies to:
Michael A. Schwartz, Esq.
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019-6099
(212) 728-8000
March 12, 2007
- --------------------------------------------------------------------------------
(Date of Event which Requires
Filing of this Schedule)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box: [ ]
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 240.13d-7 for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
- -------------------------------- ------------------
CUSIP No. 69329Y104 Page 2 of 17 Pages
- -------------------------------- ------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Third Point LLC I.D. #13-3922602
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
0
--------- ------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 10,103,600
OWNED BY --------- ------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH 0
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
10,103,600
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
10,103,600
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.8%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
OO
- ----------- --------------------------------------------------------------------
SCHEDULE 13D
- -------------------------------- ------------------
CUSIP No. 69329Y104 Page 3 of 17 Pages
- -------------------------------- ------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Third Point Offshore Fund, Ltd.
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
0
--------- ------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 6,544,000
OWNED BY --------- ------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH 0
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
6,544,000
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
6,544,000
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.7%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
OO
- ----------- --------------------------------------------------------------------
SCHEDULE 13D
- -------------------------------- ------------------
CUSIP No. 69329Y104 Page 4 of 17 Pages
- -------------------------------- ------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Daniel S. Loeb
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
0
--------- ------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 10,103,600
OWNED BY --------- ------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH 0
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
10,103,600
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
10,103,600
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.8%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- ----------- --------------------------------------------------------------------
SCHEDULE 13D
- -------------------------------- ------------------
CUSIP No. 69329Y104 Page 5 of 17 Pages
- -------------------------------- ------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Jason Aryeh
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
62,783
--------- ------------------------------------------------
NUMBER OF 8 SHARED VOTING POWER
SHARES
BENEFICIALLY 0
OWNED BY --------- ------------------------------------------------
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
PERSON WITH 62,783
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
62,783
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0.05%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- ----------- --------------------------------------------------------------------
This Amendment No. 1 to Schedule 13D ("Amendment No. 1") amends the
Schedule 13D filed on March 5, 2007 (as amended by this Amendment No. 1, the
"Schedule 13D") and is being filed on behalf of Third Point LLC, a Delaware
limited liability company (the "Management Company"), Third Point Offshore Fund,
Ltd., a Cayman Islands limited liability exempted company (the "Offshore Fund"),
Daniel S. Loeb, an individual ("Mr. Loeb", and together with the Management
Company and the Offshore Fund, the "Third Point Reporting Persons"), and Jason
Aryeh, an individual ("Mr. Aryeh", and together with the Third Point Reporting
Persons, the "Reporting Persons"). This Amendment No. 1 relates to the common
stock, par value $0.01 per share (the "Common Stock"), of PDL BioPharma, Inc., a
Delaware corporation (the "Company"). The Management Company is the investment
manager or adviser to a variety of hedge funds and managed accounts (such funds
and accounts, including the Offshore Fund, the "Funds"). The Funds directly own
the Common Stock to which this Schedule 13D relates, and Mr. Loeb and the
Management Company may be deemed to have beneficial ownership over such Common
Stock by virtue of the authority granted to them by the Funds to vote and to
dispose of the securities held by the Funds, including the Common Stock. Mr.
Aryeh may be deemed to have beneficial ownership of the shares of Common Stock
directly owned by JALAA Equities, LP ("JALAA") by virtue of his ability to vote
and/or to dispose of the securities held by JALAA, including the Common Stock.
Item 2. Identity and Background.
Items 2 of the Schedule 13D is hereby amended by adding the following
thereto:
(a) The Offshore Fund is organized as a limited liability exempted company
under the laws of the Cayman Islands. Jason Aryeh is a natural person.
(b) The address of the principal business and principal office of the
Offshore Fund is c/o Walkers SPV Limited, Walker House, 87 Mary Street, George
Town, Grand Cayman-KY1-9002, Cayman Islands, British West Indies. The business
address of Mr. Aryeh is 34 Sumner Road, Greenwich, Connecticut 06831.
(c) The principal business of the Offshore Fund is to invest and trade in
securities. The principal business of Mr. Aryeh is serving as the general
partner of JALAA.
(d) Neither the Offshore Fund nor, to the best of its knowledge, any of its
directors, executive officers, general partners or members has, nor has Mr.
Aryeh, during the last five years, been convicted in a criminal proceeding
(excluding traffic violations or similar misdemeanors).
6
(e) Neither the Offshore Fund nor, to the best of its knowledge, any of its
directors, executive officers, general partners or members has, nor has Mr.
Aryeh, during the last five years, been a party to a civil proceeding of a
judicial or administrative body of competent jurisdiction and as a result of
such proceeding was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal
or state securities laws or finding any violation with respect to such laws.
(f) Mr. Aryeh is a United States citizen.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 of the Schedule 13D is hereby amended and restated as follows:
The Funds expended an aggregate of approximately $164,666,875 of their
own investment capital to acquire the 8,450,000 shares of Common Stock held by
them (the "Shares"). The Funds expended an aggregate of approximately $3,555,443
of their own investment capital to acquire the options to purchase 1,653,600
shares of Common Stock held by them. The Offshore Fund expended an aggregate of
approximately $101,044,211 of its own investment capital to acquire its
5,178,400 shares of Common Stock. The Offshore Fund expended an aggregate of
approximately $2,978,835 of its own investment capital to acquire the options to
purchase 1,365,600 shares of Common Stock that it holds. JALAA expended an
aggregate of approximately $1,139,360 of its own investment capital to acquire
the 62,783 shares of Common Stock that it holds.
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended by adding the following
thereto:
Subsequent to delivery of Mr. Loeb's March 5, 2007 letter to the Board
expressing concerns about the Company's corporate and R&D spending and offering
to work cooperatively with the Company to address these issues, representatives
of Third Point contacted the Company to reiterate these concerns and to request
representation on the Company's Board. In a subsequent call by the Company to
representatives of Third Point, Mark McDade, chief executive officer of the
Company, indicated to the Third Point representatives that they would be welcome
to propose candidates to serve on the Board, just as would any other shareholder
of the Company.
On March 20, 2007, Mr. Loeb sent to Mr. McDade the resumes of four
individuals, including Mr. Aryeh (the "Candidates"), and requested that each of
the Candidates be added to the Company's Board of Directors. Mr. Loeb indicated
that each of the Candidates has served on other public biotechnology boards with
great success. Mr. Loeb also stated that he had been in discussions with a
prominent consulting firm and that he would
7
like the Board to retain that firm to review corporate and research and
development spending. Mr. Loeb demanded, in the transmission, a definitive
response from Mr. McDade and the PDLI board, by the close of business on
Thursday, March 22nd, as to whether they have agreed to add the four Canadians
to the Board.
Item 5. Interest in Securities of the Issuer.
Items 5(a), 5(b) and 5(c) of the Schedule 13D are hereby amended and
restated as follows:
(a) As of the date of this Schedule 13D, the Management Company
beneficially owns 10,103,600 shares of Common Stock, consisting of 8,450,000
shares of Common Stock held by the Funds (the "Third Point Shares") and
1,653,600 shares of Common Stock acquirable upon exercise of options held by the
Funds (the "Third Point Options"). The Third Point Shares and shares of Common
Stock acquirable upon exercise of the Third Point Options together represent
8.8% of the 115,265,960 shares of Common Stock outstanding as of February 22,
2007, as reported in the Company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2006. The percentages used herein and in the rest of
this statement are calculated based upon this number of outstanding shares.
As of the date of this Schedule 13D, the Offshore Fund directly
beneficially owns 6,544,000 shares of Common Stock, consisting of 5,178,400
shares of Common Stock and 1,365,600 shares of Common Stock acquirable upon
exercise of options held by it, together representing 5.7% of the outstanding
shares of Common Stock. None of the other individual Funds owns a number of
shares of Common Stock representing more than 5% of such total.
As of the date of this Amendment, Mr. Aryeh beneficially owns 62,783 shares
of Common Stock, which represent 0.05% of the outstanding shares of Common
Stock.
As a result of the matters described in Item 4, the Management Company and
Mr. Loeb may be deemed members of a group with Mr. Aryeh, and each member of
such group may be deemed to beneficially own for purposes of Section 13(d) of
the Securities Exchange Act of 1934, as amended, the shares beneficially owned
for such purposes by each other member of any such group. Accordingly, on this
basis, the Management Company, Mr. Loeb and Mr. Aryeh might each be deemed to
beneficially own, in the aggregate, 10,166,383 shares, or 8.8%, of the
outstanding shares of Common Stock. Each of the Management Company and Mr. Loeb
disclaims beneficial ownership of the Common Stock beneficially owned by Mr.
Aryeh, and any pecuniary interest therein, and Mr. Aryeh disclaims beneficial
ownership of the Common Stock beneficially owned by any of the Management
Company and Mr. Loeb, and any pecuniary interest therein.
(b) The Management Company and Mr. Loeb share voting and dispositive power
over the 10,103,600 shares of Common Stock held directly by the Funds. The
Management Company, Mr. Loeb and the
8
Offshore Fund share voting power and dispositive power over the 6,544,000 shares
of Common Stock held by the Offshore Fund. Mr. Aryeh has sole voting power and
dispositive power over the 62,783 shares of Common Stock held by JALAA.
(c) Schedules A and C hereto respectively set forth certain information
with respect to transactions by the Funds (at the direction of the Management
Company and Mr. Loeb), in the Common Stock and options to purchase since the
most recent filing on Schedule 13D.
Schedules B and D hereto respectively set forth certain information with
respect to transactions during the past 60 days by the Offshore Fund (at the
direction of the Management Company and Mr. Loeb) in the Common Stock and in
options to purchase Common Stock.
Schedule E sets forth certain information with respect to transactions by
Mr. Aryeh in the Common Stock during the past 60 days.
All of the transactions set forth on Schedules A, B, C, D and E were
effected in open market transactions. Since the most recent filing on Schedule
13D (except as set forth on Schedules A and C) and during the past 60 days
(except as set forth on Schedules B, D and E) there were no transactions in the
Common Stock or options to purchase Common Stock effected by any of the
Management Company, Mr. Loeb, the Offshore Fund or Mr. Aryeh, nor, in the case
of the Management Company and the Offshore Fund and to the best of their
knowledge, any of their directors, executive officers, general partners or
members.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect
to Securities of the Issuer.
Item 6 of the Schedule 13D is hereby amended by adding the following
thereto:
Pursuant to Rule 13d-1(k) promulgated under the Exchange Act, the Reporting
Persons have entered into an amended and restated agreement with respect to the
joint filing of this statement, and any amendment or amendments hereto.
The Funds have acquired, in open market transactions, standardized options
to purchase an aggregate of 1,653,600 shares of Common Stock of the Company.
Such shares of Common Stock can be acquired for prices of $17.50 per share or
$20.00 per share pursuant to the exercise of the such options. For further
information relating to the Third Point Options, see Item 5 and Schedules C and
D hereto.
9
Except as set forth herein, there are no contracts, arrangements,
understandings or relationships among the persons named in Item 2 or between
such persons and any other person with respect to any securities of the Company.
Item 7. Material to be Filed as Exhibits.
99.1. Amended and Restated Joint Filing Agreement, dated as of March 21,
2007, by and between the Reporting Persons.
[Signatures on following page]
10
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.
Dated: March 21, 2007
THIRD POINT LLC
By: Daniel S. Loeb,
Chief Executive Officer
By: /s/ Justin Nadler
-------------------------------
Name: Justin Nadler
Title: Attorney-in-Fact
THIRD POINT OFFSHORE FUND, LTD.
By: Daniel S. Loeb,
Director
By: /s/ Justin Nadler
-------------------------------
Name: Justin Nadler
Title: Attorney-in-Fact
DANIEL S. LOEB
By: /s/ Justin Nadler
-------------------------------
Name: Justin Nadler
Title: Attorney-in-Fact
/s/ Jason Aryeh
-----------------------------------
Jason Aryeh
[SIGNATURE PAGE TO AMENDMENT NO. 1 TO SCHEDULE 13D
WITH RESPECT TO PDL BIOPHARMA, INC.]
Schedule A
----------
(Transactions by the Funds in Common Stock
since the most recent filing on Schedule 13D)
Date Transaction Shares Price Per Share($)
---- ----------- ------ ------------------
- ----------------- ------------------- ----------------- ------------------------
3/12/2007 Buy 100,000 19.35
- ----------------- ------------------- ----------------- ------------------------
3/13/2007 Buy 175,000 19.28
- ----------------- ------------------- ----------------- ------------------------
3/19/2007 Buy 175,000 18.93
- ----------------- ------------------- ----------------- ------------------------
Schedule B
----------
(Transactions by the Offshore Fund in Common Stock
during the past 60 days)
Date Transaction Shares Price Per Share($)
---- ----------- ------ ------------------
- ----------------- ------------------- ----------------- ------------------------
1/31/2007 Buy 1,700 20.51
- ----------------- ------------------- ----------------- ------------------------
2/8/2007 Buy 160,700 19.69
- ----------------- ------------------- ----------------- ------------------------
2/12/2007 Buy 64,900 19.45
- ----------------- ------------------- ----------------- ------------------------
2/13/2007 Buy 126,000 19.35
- ----------------- ------------------- ----------------- ------------------------
2/14/2007 Buy 63,400 18.97
- ----------------- ------------------- ----------------- ------------------------
2/22/2007 Buy 188,400 19.37
- ----------------- ------------------- ----------------- ------------------------
2/22/2007 Buy 64,300 19.43
- ----------------- ------------------- ----------------- ------------------------
2/22/2007 Buy 96,400 19.59
- ----------------- ------------------- ----------------- ------------------------
2/22/2007 Buy 192,800 19.58
- ----------------- ------------------- ----------------- ------------------------
2/22/2007 Buy 64,200 19.82
- ----------------- ------------------- ----------------- ------------------------
2/23/2007 Buy 160,800 19.43
- ----------------- ------------------- ----------------- ------------------------
2/23/2007 Buy 289,400 19.42
- ----------------- ------------------- ----------------- ------------------------
2/23/2007 Buy 64,200 19.50
- ----------------- ------------------- ----------------- ------------------------
2/23/2007 Buy 98,900 19.49
- ----------------- ------------------- ----------------- ------------------------
2/26/2007 Buy 63,800 19.95
- ----------------- ------------------- ----------------- ------------------------
2/26/2007 Buy 32,100 19.90
- ----------------- ------------------- ----------------- ------------------------
2/26/2007 Buy 128,600 19.74
- ----------------- ------------------- ----------------- ------------------------
2/26/2007 Buy 96,500 19.86
- ----------------- ------------------- ----------------- ------------------------
2/26/2007 Buy 64,300 19.89
- ----------------- ------------------- ----------------- ------------------------
2/27/2007 Buy 59,900 19.36
- ----------------- ------------------- ----------------- ------------------------
2/28/2007 Buy 27,900 19.09
- ----------------- ------------------- ----------------- ------------------------
- ----------------- ------------------- ----------------- ------------------------
2/28/2007 Buy 193,400 19.21
- ----------------- ------------------- ----------------- ------------------------
2/28/2007 Buy 129,200 19.01
- ----------------- ------------------- ----------------- ------------------------
2/28/2007 Buy 32,300 19.03
- ----------------- ------------------- ----------------- ------------------------
2/28/2007 Buy 129,200 19.05
- ----------------- ------------------- ----------------- ------------------------
3/1/2007 Buy 61,600 18.76
- ----------------- ------------------- ----------------- ------------------------
3/1/2007 Buy 96,900 18.70
- ----------------- ------------------- ----------------- ------------------------
Schedule C
----------
(Transactions by the Funds since the most recent filing on
Schedule 13D in options to purchase Common Stock)
Strike Price Shares Acquirable Option Price
------------ ----------------- ------------
Date Transaction Per Share ($) Upon Exercise Per Share($)
---- ----------- ------------- ------------- ------------
- ------------ ------------- ---------------- ------------------- ----------------
3/12/2007 Buy 17.50 400,000 2.22
- ------------ ------------- ---------------- ------------------- ----------------
3/13/2007 Sell 17.50 (200,000) 1.77
- ------------ ------------- ---------------- ------------------- ----------------
3/13/2007 Buy 17.50 325,000 2.49
- ------------ ------------- ---------------- ------------------- ----------------
3/13/2007 Buy 17.50 200,000 2.40
- ------------ ------------- ---------------- ------------------- ----------------
3/14/2007 Buy 20.00 203,600 1.15
- ------------ ------------- ---------------- ------------------- ----------------
3/19/2007 Buy 17.50 325,000 2.17
- ------------ ------------- ---------------- ------------------- ----------------
Schedule D
----------
(Transactions by the Offshore Fund during the past 60 days
in options to purchase Common Stock)
Strike Price Shares Acquirable Option Price
------------ ----------------- ------------
Date Transaction Per Share ($) Upon Exercise Per Share($)
---- ----------- ------------- ------------- ------------
- ------------ ------------- ---------------- ------------------- ----------------
2/7/2007 Buy 20.00 116,800 1.45
- ------------ ------------- ---------------- ------------------- ----------------
2/8/2007 Buy 20.00 128,900 0.75
- ------------ ------------- ---------------- ------------------- ----------------
2/13/2007 Buy 17.50 128,800 2.18
- ------------ ------------- ---------------- ------------------- ----------------
3/2/2007 Buy 17.50 137,500 2.20
- ------------ ------------- ---------------- ------------------- ----------------
3/2/2007 Sell 20.00 (116,800) 0.80
- ------------ ------------- ---------------- ------------------- ----------------
3/12/2007 Buy 17.50 299,000 2.22
- ------------ ------------- ---------------- ------------------- ----------------
3/13/2007 Sell 17.50 (128,800) 1.77
- ------------ ------------- ---------------- ------------------- ----------------
3/13/2007 Buy 17.50 271,500 2.49
- ------------ ------------- ---------------- ------------------- ----------------
3/13/2007 Buy 17.50 200,000 2.40
- ------------ ------------- ---------------- ------------------- ----------------
3/14/2007 Buy 20.00 132,600 1.15
- ------------ ------------- ---------------- ------------------- ----------------
3/19/2007 Buy 17.50 325,000 2.17
- ------------ ------------- ---------------- ------------------- ----------------
Schedule E
----------
(Transactions by Mr. Aryeh in Common Stock
during the past 60 days)
Date Transaction Shares Price Per Share($)
---- ----------- ------ ------------------
- ----------------- ------------------- ----------------- ------------------------
2/15/2007 Buy 150 18.90
- ----------------- ------------------- ----------------- ------------------------
2/21/2007 Buy 1,650 18.55
- ----------------- ------------------- ----------------- ------------------------
2/27/2007 Buy 850 18.92
- ----------------- ------------------- ----------------- ------------------------
2/28/2007 Buy 250 18.78
- ----------------- ------------------- ----------------- ------------------------
3/1/2007 Buy 850 18.66
- ----------------- ------------------- ----------------- ------------------------
3/2/2007 Buy 2,800 18.40
- ----------------- ------------------- ----------------- ------------------------
3/5/2007 Buy 600 18.12
- ----------------- ------------------- ----------------- ------------------------
3/6/2007 Buy 3,900 18.29
- ----------------- ------------------- ----------------- ------------------------
3/7/2007 Buy 300 18.78
- ----------------- ------------------- ----------------- ------------------------
3/8/2007 Buy 2,100 18.80
- ----------------- ------------------- ----------------- ------------------------
3/9/2007 Buy 4,800 18.62
- ----------------- ------------------- ----------------- ------------------------
3/12/2007 Buy 23,083 19.05
- ----------------- ------------------- ----------------- ------------------------
3/13/2007 Buy 1,700 19.05
- ----------------- ------------------- ----------------- ------------------------
3/14/2007 Buy 3,700 18.97
- ----------------- ------------------- ----------------- ------------------------
3/14/2007 Sell (100) 19.08
- ----------------- ------------------- ----------------- ------------------------
3/15/2007 Buy 5,400 19.03
- ----------------- ------------------- ----------------- ------------------------
3/16/2007 Buy 7,450 18.79
- ----------------- ------------------- ----------------- ------------------------
3/19/2007 Buy 900 18.84
- ----------------- ------------------- ----------------- ------------------------
3/20/2007 Buy 1,000 18.95
- ----------------- ------------------- ----------------- ------------------------
3/21/2007 Buy 1,400 19.22
- ----------------- ------------------- ----------------- ------------------------
Exhibit 99.1
------------
AMENDED AND RESTATED JOINT FILING AGREEMENT
PURSUANT TO RULE 13d-1(k)(1)
----------------------------
The undersigned acknowledge and agree that the foregoing statement on
Schedule 13D is filed on behalf of each of the undersigned and that all
subsequent amendments to this statement on Schedule 13D shall be filed on behalf
of each of the undersigned without the necessity of filing additional joint
filing agreements. The undersigned acknowledge that each shall be responsible
for the timely filing of such amendments, and for the completeness and accuracy
of the information concerning it contained therein, but shall not be responsible
for the completeness and accuracy of the information concerning the others,
except to the extent that it knows or has reason to believe that such
information is inaccurate. This Agreement may be executed in any number of
counterparts and all of such counterparts taken together shall constitute one
and the same instrument. This Amended and Restated Joint Filing Agreement amends
and restates in its entirety that certain Joint Filing Agreement, dated as of
March 5, 2007, originally filed with the Original 13D.
Dated: March 21, 2007
THIRD POINT LLC
By: Daniel S. Loeb,
Chief Executive Officer
By: /s/ Justin Nadler
-------------------------------
Name: Justin Nadler
Title: Attorney-in-Fact
THIRD POINT OFFSHORE FUND, LTD.
By: Daniel S. Loeb,
Director
By: /s/ Justin Nadler
-------------------------------
Name: Justin Nadler
Title: Attorney-in-Fact
DANIEL S. LOEB
By: /s/ Justin Nadler
-------------------------------
Name: Justin Nadler
Title: Attorney-in-Fact
/s/ Jason Aryeh
-----------------------------------
Jason Aryeh
[AMENDED AND RESTATED JOINT FILING AGREEMENT FOR SCHEDULE 13D
WITH RESPECT TO PDL BIOPHARMA, INC.]